ALDERLEY PARK, CHESHIRE – Astrazeneca plc has sold its historic research and development home at Alderley Park, Cheshire, for development as a bioincubator and science park, as it advances the plan to bring small molecules and biologics R&D carried out by the Medimmune Inc. subsidiary together at a new $500 million global research center it is building in Cambridge.